Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
263 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015', provides an overview of the Refractory Chronic Lymphocytic Leukemia (CLL)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Chronic Lymphocytic Leukemia (CLL) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Refractory Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 7 Global Markets Direct Report Coverage 7 Refractory Chronic Lymphocytic Leukemia (CLL) Overview 8 Therapeutics Development 9 Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) - Overview 9 Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis 10 Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 11 Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes 13 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Refractory Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 17 Refractory Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes 20 Refractory Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 21 4SC AG 21 AbbVie Inc. 22 Astellas Pharma Inc. 23 Astex Pharmaceuticals, Inc. 24 AstraZeneca Plc 25 Boehringer Ingelheim GmbH 26 Bristol-Myers Squibb Company 27 Celgene Corporation 28 Cellular Biomedicine Group, Inc. 29 F. Hoffmann-La Roche Ltd. 30 Hutchison MediPharma Limited 31 ImmunoGen, Inc. 32 Immunomedics, Inc. 33 Incyte Corporation 34 Infinity Pharmaceuticals, Inc. 35 Innate Pharma SA 36 Juno Therapeutics Inc. 37 Karyopharm Therapeutics, Inc. 38 Les Laboratoires Servier SAS 39 LFB S.A. 40 Lymphocyte Activation Technologies, S.A. 41 Medicenna Therapeutics, Inc 42 MedImmune, LLC 43 Millennium Pharmaceuticals, Inc. 44 MorphoSys AG 45 Novartis AG 46 Ono Pharmaceutical Co., Ltd. 47 Portola Pharmaceuticals, Inc. 48 Sanofi 49 TG Therapeutics, Inc. 50 Threshold Pharmaceuticals, Inc. 51 Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 52 Assessment by Monotherapy Products 52 Assessment by Combination Products 53 Assessment by Target 54 Assessment by Mechanism of Action 57 Assessment by Route of Administration 60 Assessment by Molecule Type 62 Drug Profiles 64 (INCB-039110 + INCB-040093) - Drug Profile 64 4SC-202 - Drug Profile 65 acalabrutinib - Drug Profile 67 ACP-319 - Drug Profile 70 afuresertib hydrochloride - Drug Profile 71 AGS-67E - Drug Profile 73 AT-7519 - Drug Profile 74 AZD-6738 - Drug Profile 77 BI-836826 - Drug Profile 79 BMS-986016 - Drug Profile 80 buparlisib hydrochloride - Drug Profile 81 CBM-C19.1 - Drug Profile 85 CBM-C20.1 - Drug Profile 86 CC-122 - Drug Profile 88 Cellular Immunotherapy for Chronic Lymphocytic Leukaemia - Drug Profile 90 Cellular Immunotherapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia - Drug Profile 91 cerdulatinib - Drug Profile 92 duvelisib - Drug Profile 93 evofosfamide - Drug Profile 96 HMPL-523 - Drug Profile 104 IMGN-529 - Drug Profile 105 IMMU-114 - Drug Profile 107 inebilizumab + rituximab - Drug Profile 108 IPH-2201 - Drug Profile 109 JCAR-014 - Drug Profile 111 JCAR-015 - Drug Profile 112 lirilumab - Drug Profile 114 MDNA-56 - Drug Profile 116 MOR-208 - Drug Profile 117 nivolumab - Drug Profile 119 obinutuzumab - Drug Profile 126 pilaralisib - Drug Profile 129 S-055746 - Drug Profile 132 selinexor - Drug Profile 133 spebrutinib besylate - Drug Profile 138 TAK-659 - Drug Profile 140 TGR-1202 - Drug Profile 141 tisagenlecleucel-T - Drug Profile 143 trametinib dimethyl sulfoxide - Drug Profile 146 ublituximab - Drug Profile 149 ublituximab + TGR-1202 - Drug Profile 151 UC-961 - Drug Profile 152 ulocuplumab - Drug Profile 153 urelumab - Drug Profile 155 venetoclax - Drug Profile 157 Refractory Chronic Lymphocytic Leukemia (CLL) - Recent Pipeline Updates 160 Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 248 Refractory Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 249 Refractory Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 250 Featured News & Press Releases 250 Appendix 259 Methodology 259 Coverage 259 Secondary Research 259 Primary Research 259 Expert Panel Validation 259 Contact Us 259 Disclaimer 260
List of Tables
Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL), H2 2015 12 Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H2 2015 13 Number of Products under Development by Companies, H2 2015 15 Number of Products under Investigation by Universities/Institutes, H2 2015 16 Comparative Analysis by Late Stage Development, H2 2015 17 Comparative Analysis by Clinical Stage Development, H2 2015 18 Comparative Analysis by Early Stage Development, H2 2015 19 Products under Development by Companies, H2 2015 20 Products under Development by Companies, H2 2015 (Contd..1) 21 Products under Development by Companies, H2 2015 (Contd..2) 22 Products under Investigation by Universities/Institutes, H2 2015 23 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H2 2015 24 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc., H2 2015 25 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc., H2 2015 26 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals, Inc., H2 2015 27 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by AstraZeneca Plc, H2 2015 28 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H2 2015 29 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H2 2015 30 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corporation, H2 2015 31 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellular Biomedicine Group, Inc., H2 2015 32 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 33 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison MediPharma Limited, H2 2015 34 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by ImmunoGen, Inc., H2 2015 35 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics, Inc., H2 2015 36 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corporation, H2 2015 37 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Infinity Pharmaceuticals, Inc., H2 2015 38 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma SA, H2 2015 39 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc., H2 2015 40 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 41 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Les Laboratoires Servier SAS, H2 2015 42 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB S.A., H2 2015 43 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lymphocyte Activation Technologies, S.A., H2 2015 44 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Medicenna Therapeutics, Inc, H2 2015 45 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by MedImmune, LLC, H2 2015 46 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 47 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H2 2015 48 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H2 2015 49 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 50 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Portola Pharmaceuticals, Inc., H2 2015 51 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H2 2015 52 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by TG Therapeutics, Inc., H2 2015 53 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015 54 Assessment by Monotherapy Products, H2 2015 55 Assessment by Combination Products, H2 2015 56 Number of Products by Stage and Target, H2 2015 58 Number of Products by Stage and Mechanism of Action, H2 2015 61 Number of Products by Stage and Route of Administration, H2 2015 64 Number of Products by Stage and Molecule Type, H2 2015 66 Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics - Recent Pipeline Updates, H2 2015 163 Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H2 2015 251 Refractory Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H2 2015 252
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
